Cerus Corporation (NASDAQ: CERS) announced U.S. Food and Drug Administration (FDA) approval of the INTERCEPT Blood System for treatment of ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA

FBR Capital Reiterates Outperform on Cerus (CERS) Following FDA Approval March 16, 2016 10:18 AM Cerus Receives FDA Approval for Use of the INTERCEPT Blood System for Platelets Suspended in 100% PlasmaMarch 16, 2016 8:30 AM